Table 3.
Predictors of COVID-19 disease severity in patients with cancer.
|
COVID-19 Disease Severity |
||
|---|---|---|
| Predictors | OR | 95% CI |
| Unadjusted | ||
| CV Risk Factors (yes vs. no) | 3.15 | 2.91–3.41 |
| Adjusted | ||
| CV Risk Factors (yes vs. no) | 1.25 | 1.11–1.40 |
| Age | ||
| < 40 years, per decade | 0.89 | 0.75–1.04 |
| > 40 years, per decade | 1.42 | 1.42–1.56 |
| Sex | ||
| Female | Ref. | |
| Male | 1.42 | 1.31–1.54 |
| Race | ||
| Non-Hispanic White | Ref. | |
| Non-Hispanic Black | 1.26 | 1.13–1.41 |
| Hispanic | 1.30 | 1.15–1.47 |
| Other | 1.27 | 1.10–1.46 |
| BMI (kg/m2) | ||
| 18–24 | Ref. | |
| < 18.5 | 1.66 | 1.26–2.18 |
| 25–29.9 | 0.77 | 0.69–0.87 |
| 30–34.9 | 0.89 | 0.78–1.01 |
| 35–39.9 | 1.22 | 1.04–1.44 |
| >40 | 1.47 | 1.23–1.77 |
| ECOG Score | ||
| 0 | Ref. | |
| 1 | 1.46 | 1.31–1.63 |
| 2+ | 6.33 | 5.50–7.28 |
| Unknown | 1.66 | 1.49–1.85 |
| Tumor Type | ||
| Multiple | Ref. | |
| Heme | 1.10 | 0.87–1.39 |
| Solid | 0.66 | 0.53–0.82 |
| Cancer Stage | ||
| Localized | Ref | |
| Disseminated | 1.56 | 1.39–1.75 |
| Cancer Status | ||
| Remission/NED | Ref. | |
| Active and responding | 1.01 | 0.87–1.17 |
| Active and stable | 1.02 | 0.89–1.16 |
| Active and progressing | 4.01 | 3.46–4.65 |
| Unknown | 1.46 | 1.25–1.71 |
| Recent cancer therapy (vs. none) | 1.09 | 0.97–1.21 |
| Cancer Therapy (yes vs. no) | ||
| Cytotoxic chemotherapy | 1.30 | 1.15–1.46 |
| Targeted therapy | 0.99 | 0.87–1.13 |
| Immunotherapy | 1.03 | 0.85–1.40 |
| Endocrine therapy | 0.70 | 0.61–0.81 |
| Locoregional therapy | 1.25 | 1.08–1.44 |
| Baseline Cardiac Medications (yes vs. no) | ||
| ACE-I | 0.85 | 0.76–0.95 |
| ARB | 0.87 | 0.77–0.98 |
| BB | 1.24 | 1.11–1.38 |
| Statins | 1.07 | 0.97–1.17 |
| AC, ASA or APT | 1.46 | 1.33–1.60 |
| Region of COVID-19 Diagnosis US Northeast |
||
| Ref. | ||
| Non-US | 0.67 | 0.56–0.80 |
| US Midwest | 0.77 | 0.69–0.86 |
| US South | 0.80 | 0.71–0.91 |
| US West | 0.65 | 0.57–0.74 |
| Date of COVID-19 Diagnosis January–April 2020 |
||
| Ref. | ||
| May–August 2020 | 0.38 | 0.34–0.43 |
| September–December 2020 | 0.23 | 0.21–0.26 |
| January–April 2021 | 0.39 | 0.33–0.45 |
| May–August 2021 | 0.33 | 0.27–0.39 |
| September–December 2021 | 0.71 | 0.56–0.90 |
ACE-I = angiotensin-converting enzyme inhibitor, AC = anticoagulation, ARB = angiotensin receptor blocker, APT = antiplatelet therapy, ASA = aspirin, BB = beta blocker, BMI = body mass index, CV = cardiovascular, CVD = cardiovascular disease, ECOG = Eastern Cooperative Oncology Group.